International Aids Vaccine Initiative

Wyeth

Wyeth Holdings Corporation

Other

Merck Sharp + Dohme Corp.

Christopher Lee Parks

Maoli Yuan

Ivo Lorenz

Sanjay K Phogat

Aaron J Wilson

Christy Jurgens

Kevin Wright

Xinsheng Zhang

Timothy J Zamb

Wayne C Koff

Stephen Alexander Udem

Simon Hoffenberg

Maria J Chiuchiolo

Svetlana Rabinovich

Arban Domi

Makoto Inoue

Hiroto Hara

David Kirkwood Clarke

Roger Michael Hendry

Takashi Hironaka

Josephine Helena Cox

Eddy Sayeed

Angela Grazia Lombardo

Andrew J Bett

C Richter King

Amy Espeseth

Michael P Caulfield

Gerald R Kovacs

Mohinderjit S Sidhu

Ross W B Lindsay

Alexei Carpov

Olivia Wallace

Mark Feinberg

Ivo C Lorenz

Kevin J Wright

The present disclosure provides Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) vaccines, recombinant vesicular stomatitis virus (VSV) vectors encoding the SARS-CoV-2 spike (S) protein or an immunogenic variant thereof, recombinant replicable VSV particles having a SARS-CoV-2 S protein or an immunogenic variant thereof on the surface of the particles, and immunogenic recombinant proteins comprising a SARS-CoV-2 S protein or a variant thereof. Immunogenic compositions comprising the SARS-CoV-2 vaccines, the recombinant VSV vectors, the recombinant replicable VSV particles and/or the immunogenic recombinant proteins may be used for inducing an immune response to the SARS-CoV-2, preventing infection by the SARS-CoV-2, vaccinating against the SARS-CoV-2 and/or producing adaptive mutants of the recombinant replicable VSV particles.

Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Vesicular stomatitis virus and virus rescue system

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Recombinant viral vectors

The present relation relates to a transgenic Vero cell line expressing CD4 and CCR5. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Transgenic VERO-CD4/CCR5 cell line

The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.

Optimized HIV envelope gene and expression thereof

Transgenic Vero-CD4/CCR5 cell line

The present invention relates to novel canine distemper virus (CDV) neutralization-resistant mutants, methods for making the same and uses for vaccine production.

Neutralization-resistant CDV mutants and viral vectors

The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome.

Methods to improve vector expression and genetic stability

Replication-competent VSV-HIV Env vaccines

Growing community of inventors

Boonton, NJ, United States of America

Christopher Lee Parks